$MED

Kiai Parsa purchased $52K of MED (indirect holdings)

Kiai Parsa purchased 4,329 indirectly-held shares of MEDIFAST INC (MED) at $12.00 across 2 trades on 2026-08-24.

Original reporting
SEC EDGAR · Kiai Parsa
Published Aug 26, 2026, 3:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 4:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MED
Neutral
low confidence
Mentioned
$MED
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDNeutralLow
01

Why it matters

The purchase adds modest shares to the director's holdings; unlikely to move the stock.

02

Market read

Limited relevance; typical insider purchase with low material impact.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 4/10Novelty 4/10Timing: after-market filing

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$MEDNeutralLow confidence
Context

Director Kiai Parsa bought 4,329 shares of MED for $51,946, increasing his stake to 19,095 shares.

Expected impact

Minimal, likely no immediate move.

Evidence & confidence

Purchase size is modest relative to market cap; no broader catalyst.

Market effects

None

None

None

Counterpoint

Insider buying could be a subtle bullish sign despite small size.

Key entities

  • Medifast Inc.

    Manufacturer of weight‑loss and nutrition products.

  • Kiai Parsa

    Director of Medifast.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDHighAI 9/10

Why Medifast (MED) Stock Is Trading Up Today

Medifast (NYSE: MED) shares rose 37.5% after Q2 results beat expectations and the company issued a stronger full-year outlook. Medifast reported a $0.28 per-share loss versus a $0.65 expected loss, and revenue of $76.38 million. It guided full-year GAAP EPS of $1.00 at the midpoint, versus analyst estimates.

$MEDMed

MEDIFAST INC (MED): Results of Operations and Financial Condition

MEDIFAST INC (MED) filed an SEC Form 8-K — Results of Operations and Financial Condition. Medifast Announces Second Quarter 2026 Financial Results August 3, 2026 BALTIMORE – ( BUSINESS WIRE ) — Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter